pSivida (PSDV)
pSivida Revenues: 0.63M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
PSDV Revenues Rankings
| Overall | 1st percentile | 4347 of 4432 |
| Sector | 8th percentile | 429 of 471 in Healthcare |
| Industry | 9th percentile | 10 of 11 in Drug Delivery & Accessories |
PSDV Revenues Range, Past 5 Years
| Minimum | 0.10M | Sep 2007 |
| Maximum | 15.72M | Jun 2010 |
| Average | 2.552M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these PSDV related companies
PSDV News
$PSDV forms bearish "Continuation Diamond" chart pattern. http://stks.co/3l17
about 22 days ago by RecogniaEvents
about 22 days ago by RecogniaEvents
pSivida Corp. Reports Results for the Third Quarter Ended March 31, 2012
May 09, 8:00AM Business Wire
May 09, 8:00AM Business Wire
pSivida Corp Announces Third Quarter 2012 Financial Results Release Date and Conference Call Information
May 03, 9:00AM Business Wire
May 03, 9:00AM Business Wire
good time to buy $psdv on the dip it just took. other euro news should be coming soon
about 36 days ago by ingramout
about 36 days ago by ingramout
$STVF 1.65+20_4mNH $ARNA 3.20+19_53mYH $PSDV 2.38+55_1m $SHZ 1.60+14_2m $RTK 2.15+01_3mYH $VHC 25.80+77 $HRN.ca 1.66_1m http://stks.co/36S2
about 65 days ago by InvestorsGuru
about 65 days ago by InvestorsGuru
pSivida (PSDV) Rips Again; Traders Eye Further European Approval for ILLUVIEN (ALIM)
Mar 27, 12:00PM Street Insider
Mar 27, 12:00PM Street Insider
pSivida Announces Second Tech Evaluation Agreement with its BioErodible Durasert Technology
Mar 13, 8:01AM Benzinga
Mar 13, 8:01AM Benzinga
$psdv out 2.00 lost 12 cents bad trade..bad stock. bad entry, bad exit..sorry guys
about 86 days ago by kunal00
about 86 days ago by kunal00
Douglas Godshall new board of director for $psdv and $alim is boosting $psdv.
about 86 days ago by ingramout
about 86 days ago by ingramout
pSivida (PSDV) Gets Positive DCP Outcome for ILUVIEN Approval in Europe
Feb 28, 6:37AM Street Insider
Feb 28, 6:37AM Street Insider
pSivida Corp. Reports Results for the Second Quarter Ended December 31, 2011
Feb 08, 4:01PM Business Wire
Feb 08, 4:01PM Business Wire
pSivida CEO to Present at 14th Annual BioCEO & Investor Conference February 14
Feb 06, 10:30AM Business Wire
Feb 06, 10:30AM Business Wire
pSivida CEO to Participate in Panel at Glaucoma 360 Conference February 3
Feb 02, 9:10AM Business Wire
Feb 02, 9:10AM Business Wire
pSivida (PSDV) Enters Evaluation Agreement with Leading Pharma Co. for Durasert(TM)
Nov 22, 9:02AM Street Insider
Nov 22, 9:02AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| PSDV | 2.04 | -0.01 | -0.49% | 42.43M |
| PSB | 65.75 | -0.26 | -0.39% | 1.593B |
| PSAU | 33.24 | -0.41 | -1.22% | |
| PSA | 133.46 | +0.98 | +0.74% | 22.69B |
| PRXL | 26.76 | +0.45 | +1.71% | 1.566B |
| PRXI | 2.32 | +0.13 | +5.94% | 103.85M |
| PRX | 35.84 | -1.17 | -3.16% | 1.353B |
| PRWTD | 1.51 | -0.04 | -2.58% | |
| PRWT | 1.51 | -0.04 | -2.58% | 15.15M |
| PRU | 46.45 | -0.20 | -0.43% | 21.92B |
